Natera shared on LinkedIn:
“Today we announced financial results for the second quarter of 2026, marking another strong period of performance for Natera.
For the second quarter in a row, we processed over 1 million tests and had record growth in oncology.
On today’s call with the investment community, we discussed the momentum driving our business and our ability to help more patients.
That includes a series of landmark milestones and several exciting opportunities as we enter the second half of the year.
Most importantly, we remain focused on advancing our impact in each of our business areas, continuing to transform patient care for the better.”
Natera, Inc. Q2 Earnings Conference Call
Other articles about Natera on OncoDaily.
